Cornerstone gets US Bankruptcy Court okay to acquire rights to antibiotic factive from Oscient

Cornerstone Therapeutics Inc., specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, announced that it has received the approval of the United States Bankruptcy Court for the District of Massachusetts for its acquisition of the commercial rights to the antibiotic Factive (gemifloxacin mesylate) in North America and certain countries in Europe from Oscient Pharmaceuticals Corporation and expects to promptly close the transaction. 

Comments

Popular posts from this blog

Trump wants more mental health care; Alabama says it's trying

Smokefree Mumbai campaign responds to recent study by BCM, Houston that claims smoking create stronger memory